Description
Immunohistochemistry (IHC) test for PD-L1 expression using specific antibodies (22C3, SP142, SP263). Used to determine eligibility for immunotherapy with PD-1/PD-L1 inhibitors in cancers like non-small cell lung cancer (NSCLC).
In Stock
฿11,650.00
Also Known As | PD-L1 IHC, PD-L1 Immunohistochemistry, PD-L1 Add-on (22C3, SP142, SP263) |
---|---|
Specimen | FFPE Block + H and E slide + Requisition form + Pathology report ***ส่งตวั à¸à¸¢à¸²à¹ˆ งให้ BML หา้ มส่งให้ SPM |
Turnaround Time | 16 days |
Test Code | MD-NLMA645 |
Test Type | Special |
Related Tests | PD-L1 (IHC), Tumor Mutational Burden |
Immunohistochemistry (IHC) test for PD-L1 expression using specific antibodies (22C3, SP142, SP263). Used to determine eligibility for immunotherapy with PD-1/PD-L1 inhibitors in cancers like non-small cell lung cancer (NSCLC).
Guest users can Add to Cart and Checkout on the next page.
Add and Checkout feature currently supports logged-in users only.
Immunohistochemistry (IHC) test for PD-L1 expression using specific antibodies (22C3, SP142, SP263). Used to determine eligibility for immunotherapy with PD-1/PD-L1 inhibitors in cancers like non-small cell lung cancer (NSCLC).
Also Known As | PD-L1 IHC, PD-L1 Immunohistochemistry, PD-L1 Add-on (22C3, SP142, SP263) |
---|---|
Specimen | FFPE Block + H and E slide + Requisition form + Pathology report ***ส่งตวั à¸à¸¢à¸²à¹ˆ งให้ BML หา้ มส่งให้ SPM |
Turnaround Time | 16 days |
Test Code | MD-NLMA645 |
Test Type | Special |
Related Tests | PD-L1 (IHC), Tumor Mutational Burden |
Find quality services, specialists, procedures and more from the comfort of your home. All you need to do is enter a keyword or phrase describing what you are looking for.
DOWNLOAD MEDEX ONE APP
MedEx decentralizes the care continuum as a one-stop care navigation concierge, transforming the care delivery model through its Pan-Asia provider aggregation platform, primary satellite clinics, telemedicine services, and at-home health care solutions.
MedEx connects you with world-class health care providers across borders, makes medical travel simple, low-cost and transparent and offers premium primary care.
© 2020-24 MedEx Ventures Co., Ltd.